Article

Naturalistic Follow-up of Youths Treated for Pediatric Anxiety Disorders

JAMA Psychiatry (Impact Factor: 12.01). 01/2014; 71(3). DOI: 10.1001/jamapsychiatry.2013.4186
Source: PubMed

ABSTRACT Importance
Pediatric anxiety disorders are highly prevalent and impairing and are considered gateway disorders in that they predict adult psychiatric problems. Although they can be effectively treated in the short term, data are limited on the long-term outcomes in treated children and adolescents, particularly those treated with medication.Objective
To determine whether acute clinical improvement and treatment type (ie, cognitive behavioral therapy, medication, or their combination) predicted remission of anxiety and improvement in global functioning at a mean of 6 years after randomization and to examine predictors of outcomes at follow-up.Design, Setting, and Participants
This naturalistic follow-up study, as part of the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS), was conducted at 6 academic sites in the United States and included 288 youths (age range, 11-26 years; mean age, 17 years). Youths were randomized to 1 of 4 interventions (cognitive behavioral therapy, medication, combination, or pill placebo) in the Child/Adolescent Anxiety Multimodal Study (CAMS) and were evaluated a mean of 6 years after randomization. Participants in this study constituted 59.0% of the original CAMS sample.Exposures
Participants were assessed by independent evaluators using a semistructured diagnostic interview to determine the presence of anxiety disorders, the severity of anxiety, and global functioning. Participants and their parents completed questionnaires about mental health symptoms, family functioning, life events, and mental health service use.Main Outcomes and Measures
Remission, defined as the absence of all study entry anxiety disorders.Results
Almost half of the sample (46.5%) were in remission a mean of 6 years after randomization. Responders to acute treatment were significantly more likely to be in remission (odds ratio, 1.83; 95% CI, 1.08-3.09) and had less severe anxiety symptoms and higher functioning; the assigned treatment arm was unrelated to outcomes. Several predictors of remission and functioning were identified.Conclusions and Relevance
Youths rated as responders during the acute treatment phase of CAMS were more likely to be in remission a mean of 6 years after randomization, although the effect size was small. Relapse occurred in almost half (48%) of acute responders, suggesting the need for more intensive or continued treatment for a sizable proportion of youths with anxiety disorders.Trial Registration
clinicaltrials.gov Identifier: NCT00052078

Download full-text

Full-text

Available from: Courtney Pierce Keeton, Aug 26, 2014
2 Followers
 · 
99 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Anxiety disorders are the most common psychiatric disorders of childhood, generate significant distress, are considered precursors to diverse psychiatric disorders, and lead to poor social and employment outcomes in adulthood. Although childhood anxiety has a significant impact on a child's developmental trajectory, only a handful of studies examined the long-term impact of treatment and none included a control group. The aim of this study was to conduct a long-term follow-up (LTFU) of anxious children who were treated with Cognitive–Behavioral Therapy (CBT) compared to a matched group of children who were not.Methods Subjects comprised 120 children: a treatment group which included the first 60 consecutive consenting children who were diagnosed with an anxiety disorder and treated with CBT between the years 1997 and 2003 and a control group, 60 matched children who were assessed but not treated with CBT. An “ex-post-facto” design was used to compare the two groups.ResultsChildren showed lower rates of anxiety diagnosis (about 50% for both groups) and significantly improved functioning at LTFU (time effect P < 0.0001; no group difference). Anxiety levels were significantly lower in the nontreatment group at LTFU as compared to initial assessment (P = 0.02), but not in the treatment group, and a significant between-group difference was found (P = 0.01) according to child. An inverse relationship was found between self-efficacy/self-esteem and anxiety outcome ([P = 0.0008] and [P = 0.04], respectively).Conclusions This study supports the assumption that childhood anxiety disorders may improve without treatment and highlights self-efficacy/self-esteem as potential factors in recovery.
    09/2014; 4(5). DOI:10.1002/brb3.274
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Anxiety disorders are relatively common psychiatric illnesses in children and adolescents. In young people, such disorders are likely to show severe outcomes and adversely impact on multiple aspects of personality and social integration. Area covered: This article aims to analyze systematically the efficacy of both old- and new-generation antidepressants in children and adolescents diagnosed with non-obsessive–compulsive disorder anxiety disorders. Expert opinion: Reviewed data demonstrate that social phobia is the only pediatric anxiety disorder whose response to antidepressant medications has been investigated in an adequate number of studies. In this clinical condition, venlafaxine and fluoxetine (and fluvoxamine as second choice) are the only antidepressants that have shown convincing reports on efficacy. In contrast, apart from preliminary observations suggesting the efficacy of sertraline in pediatric generalized anxiety disorder, no evidence-based information definitively supports the use of antidepressants for managing other juvenile anxiety disorders.
    Expert Opinion on Drug Safety 05/2014; 13(6). · 2.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Anxiety disorders are relatively common psychiatric illnesses in children and adolescents. In young people, such disorders are likely to show severe outcomes and adversely impact on multiple aspects of personality and social integration. Area covered: This article aims to analyze systematically the efficacy of both old- and new-generation antidepressants in children and adolescents diagnosed with non-obsessive-compulsive disorder anxiety disorders. Expert opinion: Reviewed data demonstrate that social phobia is the only pediatric anxiety disorder whose response to antidepressant medications has been investigated in an adequate number of studies. In this clinical condition, venlafaxine and fluoxetine (and fluvoxamine as second choice) are the only antidepressants that have shown convincing reports on efficacy. In contrast, apart from preliminary observations suggesting the efficacy of sertraline in pediatric generalized anxiety disorder, no evidence-based information definitively supports the use of antidepressants for managing other juvenile anxiety disorders.
    Expert Opinion on Drug Safety 06/2014; 13(6):735-44. DOI:10.1517/14740338.2014.908849 · 2.74 Impact Factor